Form 4: United Therapeutics EVP Paul Mahon Executes Stock Option and Sells Shares Under 10b5-1 Plan
SEC Form 4
Paul Mahon, EVP & General Counsel of United Therapeutics, exercised stock options and sold shares of common stock on April 3, 2025, according to a Form 4 filing with the SEC.
Summary
- On April 3, 2025, Paul A. Mahon, EVP & General Counsel of United Therapeutics Corp, executed a transaction involving the company's common stock.
- Mahon exercised stock options for 11,000 shares at a price of $117.76 per share.
- Following the exercise, Mahon sold a total of 11,000 shares in multiple transactions at prices ranging from $298 to $308.0811.
- These sales were executed under a pre-arranged 10b5-1 plan adopted on December 24, 2024.
- After these transactions, Mahon directly owns 36,781 shares of United Therapeutics Corp common stock.
Sentiment
Score: 5
Explanation: The sentiment is neutral as this is a routine disclosure of insider trading activity under a pre-arranged plan. It doesn't inherently indicate a positive or negative outlook for the company.
Industry Context
This filing is a routine disclosure of insider transactions. It is common for executives to utilize 10b5-1 plans to manage their stock holdings and avoid accusations of insider trading. The transactions themselves don't necessarily indicate a positive or negative outlook for the company.
Comparison to Industry Standards
- Executive compensation practices, including stock options and 10b5-1 trading plans, are common across publicly traded companies, particularly in the biotech and pharmaceutical industries.
- Companies like Amgen, Gilead Sciences, and Biogen also have executives who utilize similar strategies for managing their equity holdings.
- The specific details of these plans, such as the exercise price and vesting schedules, can vary widely based on company performance and individual agreements.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership, but the pre-arranged nature of the sales mitigates any significant concerns.
Key Dates
| Date | Description |
|---|---|
| 12/24/2024 | Date of adoption of the 10b5-1 plan. |
| 03/15/2021 | Date the stock options were exercisable. |
| 03/15/2027 | Expiration date of the stock options. |
| 04/03/2025 | Date of stock option exercise and share sales. |
| 04/07/2025 | Date of signature on the Form 4 filing. |
Keywords
Form 4, United Therapeutics, Stock Options, Paul Mahon, 10b5-1 Plan, Executive Compensation, Insider Trading, UTHR, Share Sale
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.